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Background: Saliva evaluation could be a possible alternative to blood and/or tissue analyses, for researching 
specific molecules associated to the presence of systemic diseases and malignancies.
The present systematic review has been designed in order to answer to the question “are there significant associa-
tions between specific salivary biomarkers and diagnosis of systemic diseases or malignancies?”.
Materials and Methods: The Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) 
statement was used to guide the review.
The combinations of “saliva” and “systemic diseases” or “diagnosis” or “biomarkers” or “cancers” or “carcinoma” 
or “tumors”, were used to search Medline, Scopus and Web of Science databases. Endpoint of research has been 
set at May 2019. 
Studies were classified into 3 groups according to the type of disease investigated for diagnosis: 1) malignant 
tumors; 2) neurologic diseases and 3) inflammatory/metabolic/cardiovascular diseases.
Assessment of quality has been assigned according to a series of questions proposed by the National Institute of 
Health. Level of evidence was assessed using the categories proposed in the Oxford Center for Evidence-Based 
medicine (CEMB) levels for diagnosis (2011).
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Material and Methods
The Preferred Reporting Item for Systematic Re-
views and Meta-analysis (PRISMA) statement was 
used to guide this systematic review (98).
- Search strategy
The combinations of “saliva” and “systemic diseas-
es” or “diagnosis” or “biomarkers” or “cancers” or 
“carcinoma” or “tumors”, have been used for search-
ing Medline, Scopus and Web of Science databases. 
Only English literature was searched. We considered 
articles published after 2000 (endpoint of research 
has been set at May 2019). Periodic screening of the 
databases was performed, between September 2017 
and May 2019.
- Inclusion and exclusion criteria
Only papers reporting details on salivary sampling 
and biochemical analysis were included. Papers se-
lected were primarily focused on the use of saliva 
for diagnostic purposes. We only included studies 
performed on humans, detailing the disease of pa-
tients and providing precise information on diagno-
sis. Studies reporting data on at least 5 patients were 
included.
Case reports, conference proceedings and personal 
communication were excluded.
Studies dealing with biomarkers evaluated for ther-
apy, prognosis or staging of systemic diseases were 
not included.
We excluded researches specifically investigating 
salivary biomarkers in patients with systemic diseas-
es with oral, oropharyngeal and esophageal involve-
ment. Such a choice was taken in order to exclude 
presence of pathologies in the proximity of the site of 
saliva collection, thus avoiding confounding factors 
(e.g. contamination with peripheral molecules not 
originally presents in the salivary secrete).
Papers dealing with systemic microbial infections, 
hormones, drug dosage, were further excluded.
We excluded studies specifically reporting on bio-
chemical methods, technological aspects, devices 
used or proposed for saliva evaluation or detection of 
specific molecules.
The criteria are summarized in Table 1.
Introduction
Currently, one of the most relevant targets of medi-
cine and healthcare is early diagnosis. Detecting a 
disease at an early stage may improve the possibility 
of success of treatment, prevent complications and 
enhance prognosis and quality of life (1).
The concept of “point-of-care diagnosis” includes 
a field of investigation that explores technologies 
allowing patients and health providers to gain ac-
tionable medical information rapidly and conve-
niently (1).
The term “precision medicine” refers to the uses of 
molecular profiles, genomic, transcriptomic, pro-
teomic and metabolomic, to adapt a personalized 
therapeutic strategy for peculiar patients: a. in the 
right moment, b. to determine the predisposition to 
diseases, and c. to provide timely and targeted pre-
vention (2).
The combination of such profiles and the identifica-
tion of biomarkers is leading to the development of 
new technologies, based on easy and non-invasive 
methods to collect diagnostic human specimens, pos-
sibly with a high specificity and sensitivity and cus-
tomized on single patient.
In the last ten years, research has focused on the use 
of biomarkers in a previously poorly investigated hu-
man fluid: saliva.
Saliva is a fluid constantly produced by salivary 
glands and It has a complex molecular composition. 
Saliva is abundantly delivered in the oral cavity, its 
collection being simple and non-invasive. Moreover, 
transportation and storing are easy. For such reasons, 
saliva evaluation could be considered as a possible 
alternative to blood and/or tissue analyses, for re-
searching specific molecules (DNA, RNA, proteins 
and metabolites) associated to the presence of sys-
temic diseases and malignancies (3).
The present systematic review has been designed in 
order to answer to the question “are there significant 
associations between specific salivary biomarkers 
and diagnosis of systemic diseases or malignancies?”, 
formulated according to the “Patient-Intervention-
Comparison-Outcome” (PICO) worksheet.
Results: Seventy-nine studies met the inclusion and exclusion criteria. Fifty-one (64%) investigated malignant tu-
mors, 14 (17.5%) neurologic and 14 (18.5%) inflammatory/cardiovascular/metabolic diseases.
Among studies investigating malignant tumors, 12 (23.5%) were scored as “good” and 11 of these reported statisti-
cally significant associations between salivary molecules and pathology. Two and 5 studies were found to have a 
good quality, among those evaluating the association between salivary biomarkers and neurologic and inflammatory/
metabolic/cardiovascular diseases, respectively.
Conclusions: The present systematic review confirms the existence of some “good” quality evidence to support the 
role of peculiar salivary biomarkers for diagnosis of systemic diseases (e.g. lung cancer and EGFR).
Key words: Salivary diagnostics, biomarkers, systemic diseases, malignant tumors, early diagnosis.
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Table 1: Inclusion and exclusion criteria.
- Data extraction
Titles and abstracts were screened by two independent 
investigators. Equivocal titles/abstracts were included 
for full-text evaluation.
Reviews of literature addressing the topic of salivary 
biomarkers and diagnosis of systemic diseases and ma-
lignant tumors were carefully read and all references 
were screened in order to include papers possibly not 
selected through the entry terms used within the data-
bases. Other relevant literature was identified from the 
reference lists of the retrieved articles.
Information extracted from each study were summa-
rized in an Excel® table and they included title, cita-
tion date (authors, publication year), pathology inves-
tigated, type of biomarkers, device used to analyze the 
sample, results and presence of statistically significant 
association.
- Data analysis
Studies were assessed for overlapping series of pa-
tients on the basis of the recruitment Centre and period. 
Wherever multiple studies reported the same set of data 
in fully detectable overlapping series of patients, only 
the most recent or the most complete series was includ-
ed in the review.
Studies were classified into 3 groups according to the 
type of disease investigated for diagnosis: 1) malignant 
tumors; 2) neurologic diseases and 3) inflammatory/
metabolic/cardiovascular diseases.
- Quality assessment and critical appraisal
Assessment of quality has been assigned according to 
a series of questions proposed by the National Institute 
of Health (NIH) for each typology of study (controlled 
intervention studies, systematic reviews and meta-anal-
ysis, observational cohort and cross-sectional studies, 
case control studies, before-after studies with no control 
group, case series studies) (4).
Critical appraisal has been summarized through assig-
nation of a value ranging from 0 to 100% to each of the 
study selected, based on the percentage of “yes” choices 
on the overall number of answers given. Furthermore, 
the number of patients enrolled in each study was taken 
into consideration.
Studies with a percentage of quality ranging from 80 
to 100% were defined as “good”. Studies with a quality 
ranging between 50 and 80% were defined as “fair” and 
studies scoring less than 50% in quality were defined 
as “poor”.
Level of evidence was assessed using the categories 
proposed in the Oxford Center for Evidence-Based 
medicine (CEMB) levels for diagnosis [2011] (5).
Disagreement were resolved by discussion between the 
reviewers.
Results
The systematic literature search provided 79 studies 
which met the inclusion and exclusion criteria.
Seventy-five papers were case-control studies and 4 
case-series studies.
Fifty-one (64%) papers were focused on malignant tu-
mors, 14 (17.5%) papers on neurologic diseases and 14 
(18.5%) on inflammatory/cardiovascular/metabolic dis-
eases (Table 2, Table 3, Table 4).
Molecules investigated were DNA, RNA, proteins, me-
tabolites, microbiota and combination of these.
Results of search strategy are summarized in Fig. 1.
INCLUSION CRITERIA EXCLUSION CRITERIA
1) The study should provide information on:
Saliva sample
Biochemical analysis
Biomarkers used for diagnostic purpose
2) Human subjects
3)Precise information on diseases investigated
4) Study population on at least 5 patients
1) Case reports, conference proceedings and personal communication
2) Biomarkers used for therapeutic, prognosis or staging purpose
3) Diseases with oral, oropharyngeal and esophageal involvement
4) Papers dealing with microbial infections, hormones, drug dosage
5) Studies on animal model or in vitro
6) Studies on biochemical methods, technological aspects, devices
Fig. 1: Search strategy.
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Table 2: Papers on salivary biomarkers for diagnosis of malignant tumors.
Authors and year Title
Streckfus C et al. (2000) (28) A Preliminary Study of CAl5-3, c-erbB-2, Epidermal Growth Factor Receptor, Ca-
thepsin-D, and p53 in Saliva Among Women with Breast Carcinoma
Turan T  et al.  (2005) (29) Free and Total Prostate-Specific Antigen Levels in Saliva and the Comparison with 
Serum Levels in Men
Streckfus C et al (30) The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up 
of breast cancer in women: the results of a five-year translational research study
Streckfus C et al.  (2006) (28) The use of surface-enhanced laser desorption/ionization time-of-flight mass spec-
trometry to detect putative breast cancer markers in saliva: a feasibility study
Brooks MN  et al.  (2008) (31) Salivary protein factors are elevated in breast cancer patients
Wu ZZ  et al  (2009) (25) Diagnostic model of saliva protein finger print analysis of patients with gastric cancer
Agha-Hosseini F  et al. (2009) (32) Correlation of serum and salivary CA15-3 levels in patients with breast cancer
Sugimoto M  et al.  (2009) (33) Capillary electrophoresis mass spectrometry-based saliva metabolomics identified 
oral, breast and pancreatic cancer-specific profiles
Zhang L et al.  (2009) (12) Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer
Xiao H  et al. (2012) (54) Proteomic analysis of human saliva from lung cancer patients using two-dimension-
al difference gel electrophoresis and mass spectrometry
Lee YH   et al. (2012) (55) Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papil-
lary adenocarcinoma
Zhang L   et al. (2012) (56) Discovery and preclinical validation of salivary transcriptomic and proteomic bio-
markers for the non-invasive detection of breast cancer
Li X  et al. (2012) (57) Spectral analysis of human saliva for detection of lung cancer using surface en-
hanced Raman spectroscopy
Zhang L  et al. (2012) (8) Development of transcriptomic biomarker signature in human saliva to detect lung 
cancer
De Abreu Pereira D et al. (2012) (58) Measurement of HER2 in saliva of women in risk of breast cancer
Holten-Andersen L   et al.  (2012) (14) Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study
Laidi F  et al.  (2014) (7) Salivary expression of soluble HER2 in breast cancer patients with positive and 
negative HER2 status
Wei F  et al. (2014) (10) Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer
Chen D  et al.  (2014) (59) Saliva as a sampling source for the detection of leukemic fusion transcripts
Xie Z  et al. (2014) (13) Salivary microRNAs show potential as a noninvasive biomarker for detecting re-
sectable pancreatic cancer
Feng S et al. (2015) (6) Surface-enhanced Raman spectroscopy of saliva proteins for the noninvasive dif-
ferentiation of benign and malignant breast tumors
Cheng F  et al.  (2015) (60) Investigation of salivary free amino acid profile for early diagnosis of breast cancer 
with ultra performance liquid chromatography-mass spectrometry
Humeau M  et al.  (2015) (61) Salivary MicroRNA in Pancreatic Cancer Patients
Yan X  et al. (2015) (62) Discovery and validation of potential bacterial biomarkers for lung cancer
Delmonico L  et al. (2015) (63) CDKN2A (p14(ARF)/p16(INK4a)) and ATM promoter methylation in patients with 
impalpable breast lesions
Takayama T  et al. (2015) (64) Diagnostic approach to breast cancer patients based on target metabolomics in saliva 
by liquid chromatography with tandem mass spectrometry
Torres PJ  et al.  (2015) (65) Characterization of the salivary microbiome in patients with pancreatic cancer
Wood N  et al. (2015) (66) The Expression of Lung Resistance Protein in Saliva: A Novel Prognostic Indicator 
Protein for Carcinoma of the Breast
Tsutsui H  et al. (2016) (67) High-throughput LC-MS/MS based simultaneous determination of polyamines in-
cluding N-acetylated forms in human saliva and the diagnostic approach to breast 
cancer patients
Xiao H   et al. (2016) (49) Differential Proteomic Analysis of Human Saliva using Tandem Mass Tags Quanti-
fication for Gastric Cancer Detection
Pu D   et al. (2016) (40) Evaluation of a novel saliva-based epidermal growth factor receptor mutation detec-
tion for lung cancer: A pilot study
Xie z  et al.  (2016) (68) Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer
Zhong L  et al.  (2016) (69) Untargeted saliva metabonomics study of breast cancer based on ultra performance liq-
uid chromatography coupled to mass spectrometry with HILIC and RPLC separations
Machida T  et al (2016) (70) MiR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancrea-
tobiliary tract cancer
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Liu HJ  et al (2016) (71) Predicting novel salivary biomarkers for the detection of pancreatic cancer using 
biological feature-based classification
Shu J  et al. (2017) (15) Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer
Bel’skaya  et al. (2017) (72) The activity of metabolic enzymes in the saliva of lung cancer patients
Sun Y  et al. (2017) (73) Systematic comparison of exosomal proteomes from human saliva and serum for the 
detection of lung cancer
Laidi F  et al. (2017) (74) Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers 
HER2 and MUC1 in Breast Cancer Screening
Hernández-Arteaga A et al. (2017) (75) Diagnosis of breast cancer by analysis of sialic acid concentrations in human saliva 
by surface-enhanced Raman spectroscopy of silver nanoparticles
Cavaco C  et al. (2018) (76) Screening of salivary volatiles for putative breast cancer
discrimination: an exploratory study involving geographically distant populations
Sun J  et al. (2018) (16) A screening method for gastric cancer by oral microbiome detection
Zermeño-Nava JJ  et al. (2018) (77) Determination of sialic acid in saliva by means of surface-enhanced Raman spec-
troscopy as a marker in adnexal mass patients: ovarian cancer vs benign cases
Li F  et al. (2018) (17) Discovery and Validation of Salivary Extracellular RNA Biomarkers for Noninva-
sive Detection of Gastric Cancer
Yang J  et al. (2018) (11) Dysbiosis of the Salivary Microbiome Is Associated With Non smoking Female 
Lung Cancer and Correlated With Immunocytochemistry Markers
Tajmul M  et al. (2018) (78) Identification and validation of salivary proteomic signatures for non-invasive de-
tection of ovarian cancer
Zhang J  et al. (2018) (79) Identification of Abnormal Fucosylated-Glycans Recognized by LTL in Saliva of 
HBV-Induced Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma
Shu J   et al. (2018) (48) Identification of N- and O-linked glycans recognized by AAL in saliva of patients 
with atrophic gastritis and gastric cancer
Xie Z   et al. (2018) (80) Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocel-
lular Carcinoma
Chen Y   et al. (2018) (47) Salivary Analysis Based on Surface Enhanced Raman Scattering Sensors Distin-
guishes Early and Advanced Gastric Cancer Patients from Healthy Persons
Koizumi T  et al. (2018) (9) Salivary cytokine panel indicative of non-small cell lung cancer
Table 2 cont.: Papers on salivary biomarkers for diagnosis of malignant tumors.
Authors and year Title
Devic I  et al.  (2011) (81) Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease
Tsuruoka M  et al.  (2013) (82) Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and sa-
liva from neurodegenerative dementia patients
Al-Nimer MS  et al (2014) (83) Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in As-
sessment Biomarkers of Parkinson’s Disease
Masters JM et al. (2015) (18) Elevated salivary protein in Parkinson’s disease and salivary DJ-1 as a potential marker of 
disease severity
Liang Q  et al.  (2015) (84) Metabolomics-based screening of salivary biomarkers for early diagnosis of Alzheimer’s disease
Liang Q  et al.  (2016) (85) High-throughput metabolomics analysis discovers salivary biomarkers for predicting mild 
cognitive impairment and Alzheimer’s disease
Yilmaz A  et al.  (2017) (86) Diagnostic Biomarkers of Alzheimer’s Disease as Identified in Saliva using 1H NMR-Based 
Metabolomics.
Ashton NJ et al.  (2018) (87) No association of salivary total tau concentration with Alzheimer’s disease
Cao Z  et al.  (2018) (88) α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease
Ahmadi-Motamayel F  et al. 
(2018) (19)
Evaluation of salivary acetylcholinesterase and
pseudocholinesterase in patients with Alzheimer’s disease: A case–control study
Song W  et al. (2018) (89) Evaluation of Salivary Heme Oxygenase-1 as a Potential Biomarker of Early Parkinson’s 
Disease
Manconia B  et al. (2018) (90) Top-down proteomic profiling of human saliva in multiple sclerosis patients
Vivacqua G  et al. (2019) (37) Salivary alpha-synuclein in the diagnosis of Parkinson’s disease and Progressive Supra-
nuclear Palsy
Marksteiner J  et al. (2019) (38) Acyl-Alkyl Phosphatidlycholines are Decreased in Saliva of Patients with Alzheimer’s Dis-
ease as Identified by Targeted Metabolomics
Table 3: Papers on salivary biomarkers for diagnosis of neurologic diseases.
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Authors and year Title
Rao PV  et al. (2008) (35) Proteomic identification of salivary biomarkers of type-2 diabetes
Floriano PN.  et al  (2009) (23) Use of Saliva-Based Nano-Biochip Tests for Acute Myocardial Infarction at the Point of 
Care: A Feasibility Study
Giusti L.  et al. (2010) (26) Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis?
Buduneli E et al.  (2011) (91) Acute myocardial infarction is reflected in salivary matrix metalloproteinase-8 activation level.
Silva DG et al.  (2011) (92) Higher levels of salivary MUC5B and MUC7 in individuals with gastric diseases who 
harbor Helicobacter pylori
Mirzaii-Dizgah I  et al.  (2011) (21) Unstimulated whole saliva creatine phosphokinase in acute myocardial infarction
Mirzaii-Dizgah I  et al.  (2011) (24) Serum and saliva levels of cathepsin L in patients with acute coronary syndrome.
Mirzaii-Dizgah I  et al.  (2012) (22) Saliva-based creatine kinase MB measurement as a potential point-of-care testing for 
detection of myocardial infarction.
Mirzaii-Dizgah I  et al.  (2013) (20) Salivary high-sensitivity cardiac troponin T levels in patients with acute myocardial infarction
Mirzaii-Dizgah I  et al.  (2013) (93) Salivary troponin I as an indicator of myocardial infarction
Adornetto G  et al.  (2015) (94) An electrochemical immunoassay for the screening of celiac disease in saliva samples
Cao G  et al.  (2015) (95) A potential method for non-invasive acute myocardial infarction detection based on saliva 
Raman spectroscopy and multivariate analysis.
Giusti L  et al.  (2015) (96) Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a 
large cohort of systemic sclerosis patients
Lu C  et al.  (2017) (97) Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of pri-
mary biliary cholangitis
Table 4: Papers on salivary biomarkers for diagnosis of inflammatory/cardiovascular/metabolic diseases.
- Critical appraisal of the selected papers
Following the NIH guidelines modified according to the 
methodology of the present systematic review, 19 (24%) 
studies were scored as “good”, 45 (57%) were “fair” and 
15 (19%) had “poor” quality.
The most frequently encountered risk of bias (ROBs) 
were the absence of concurrent controls (71 papers), the 
lack of sample size justification (70 papers), the lack 
of randomization (70 papers) and absence of report of 
blinding exposure assessors (68 papers).
- Level of evidence
Application of the Oxford CEMB guidelines highlight-
ed that all of the selected papers have a low level of evi-
dence (4 on 5, the fifth level being the lowest), because 
of their case control or case series design.
- Malignant tumors
Breast cancer was the most investigated disease (18 pa-
pers), followed by lung cancer (10 papers), gastric can-
cer (7 papers) and pancreatic cancer (6 papers). Other 
cancers included leukemia, prostate, ovarian, colorec-
tal, pancreatobiliary and hepatocellular cancer.
Molecules most frequently investigated were proteins 
and RNA.
Twelve studies (23.5%) were scored as “good” and 11 of 
these reported statistically significant associations be-
tween molecules searched and pathology (6-17).
The twelve studies are summarized in Table 5.
- Neurologic diseases
Fourteen papers were focused on neurologic diseases. 
Among these, 7 papers investigated Alzheimer’s disease, 6 
investigated Parkinson’s diseases and one multiple sclerosis.
Two papers were scored as “good”. One study searched 
DJ-1 proteins in Parkinson’s patients (not statistically 
significant association) (18). The other one analyzed 
salivary metabolites in patient with Alzheimer’s disease 
and found a statistically significant association between 
disease and biomarkers (19).
Details on such papers are reported in Table 6.
- Inflammatory/cardiovascular/metabolic diseases
Fourteen papers were included in this category, the pa-
thologies investigated being diabetes, myocardial in-
farction, rheumatoid arthritis, gastric diseases, celiac 
disease and coronary syndrome.
Myocardial infarction was the most frequently studied 
disease (7 papers, 50%).
“Good” quality articles were 5, four focused on myo-
cardial infarction and one on coronary syndrome. All 
studies searched for proteins and 5 of these reported 
significant results. (20-24)
Papers are summarized in Table 7.
- Biochemical technologies
It goes beyond the aim of the present systematic review 
to critically discuss the biochemical mehods utilized in 
the studies included.
Almost all the studies on genetic molecules used Poly-
merase Chain Reaction (PCR) technique.
The studies on proteins used mainly Enzyme-Linked 
Immunosorbent Assays (ELISA) or Mass Spectrometry 
(MS). Few studies used Surface Enhanced Raman Scat-
tering (SERS) and Luminex.
For searching metabolites, the preferred technique 
was MS.
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AUTHORS AND 
YEAR
PATHOLOGY CATEGORY OF 
MOLECULE
BIOMARKERS ASSOCIATION
Xie Z. et al.  (2014) 
(13)
Pancreatic cancer RNA miR-3679-5p, miR-940 Significant (p<0.008)
Zhang L. et al. 
(2009) (12)
Pancreatic cancer RNA KRAS, MBD3L2, ACRV1, 
DPM1*
Significant (p<0.0001)
Wei F. et al. (2014) 
(10)
Lung cancer DNA EGFR** Significant (p<0.0001)
Zhang L. et al
(2012) (8)
Lung cancer RNA CCNI, EGFR, FRS2, GREB1*** Significant (p<0.05)
Yang J. Et al. 
(2018) (11)
Lung cancer microbiome sphingomonas, blastomonas, aci-
netobacter, streptococcus
Significant (p<0.05, 0.0001, 
0.01)
Koizumi T. et al. 
(2018) (9)
Lung cancer proteins/aa°° Cytokine (IL1RN, IL1B, IL6, IL7, 
IL8, IL10, CCL1, TNF, CXCL10, 
CC3, CC4, PDGF BB)****
Significant (p<0.05)
Feng S. et al. 
(2015) (6)
Breast cancer proteins/aa phenylalanine, triptophane, tyro-
sine, proline, collagene
Significant (p<0.05)
Laidi F. et al. 
(2014) (7)
Breast cancer proteins/aa HER2***** Not Significant  (p>0.05)
Holten-Andersen 
et al. (2012) (14)
Colorectal cancer proteins/aa TIMP-1****** Not significant (p=0.52)
Sun J. et al. (2018) 
(16)
Gastric cancer microbiome prevotella, leptotrichia, rothia, 
aggregatibacter, campylobacter, 
megasphaera, granulicatella
Significant (p<0.04, p<0.01, 
p<0.005)
Li F. et al. 
(2018) (17)
Gastric cancer RNA SPINK7, PPL, SEMA4B, miR-
140-5p, miR301a
Significant (p<0.05)
Shu J. et al. (2017) 
(15)
Gastric cancer proteins/aa Glycoproteins Significant (p<0.01)
* KRAS: Kirsten RAt Sarcoma virus; MBD3L2:  Methyl-CpG Binding Domain Protein 3 Like 2; ACRV1: acrosomal vesicle protein 1; DPM1: 
Dolichyl-Phosphate Mannosyltransferase Subunit 1; **EGFR: epidermal growth factor receptor; ***CCNI: cyclin-1 gene; FRS2: Fibroblast 
growth factor receptor substrate 2 gene; GREB1: Growth regulation by estrogen in breast cancer 1 gene; **** IL1RN: interleukin receptor 
antagonist, CCL11: C-C motif chemokine ligand 11, TNF: tumor necrosis factor, CXCL10: C-X-C motif chemokine ligand 10, CC3: C-C mo-
tif chemokine ligand 3 , CC4: C-C motif chemokine ligand 4, PDGF BB: platelet-derived growth factor-BB; *****HER2: human epidermal 
growth factor receptor 2; ******TIMP-1:   tissue inhibitor of metalloproteinases 1; °° aa: aminoacids.
Table 5: Good quality studies on salivary biomarkers for diagnosis of malignant tumors.
Table 6: Good quality studies on salivary biomarkers for diagnosis of neurologic disease.
AUTHORS AND YEAR PATHOLOGY CATEGORY OF 
MOLECULE
BIOMARKERS ASSOCIATION
Masters J.M. et al. (2015) 
(18)
Parkinson’s disease proteins/aa** DJ-1* Not significant (p=0.6)
Ahmadi-Motamayel F. et 
al. (2018) (19)
Alzheimer’s disease metabolites acetylcholinesterase, 
pseudocholinesterase
Significant (p<0.002)
*DJ-1 : Proteine deglycase DJ1
** aa: aminoacids
Table 7: Good quality studies on salivary biomarkers for diagnosis of inflammatory/cardiovascular/metabolic diseases.
AUTHORS AND 
YEAR
PATHOLOGY CATEGORY OF 
MOLECULE
BIOMARKERS ASSOCIATION
Floriano P. et Al
(2009) (23)
Myocardial infarction proteins/aa** C-RP, MYO, MPO* Significant (p>0.0001)
Mirzaii-Dizgah et Al
(2011) (21)





Myocardial infarction proteins/aa Creatin kinase MB (CK-MB) Significant (p<0.001)
Mirzaii-Dizgah et Al
(2012) (20)
Myocardial infarction proteins/aa Cardiac troponin T Significant (p<0.02)
Mirzaii-Dizgah et Al 
(2011) (24)
Coronary syndrome proteins/aa Cathepsin-L Not significant (p=0.02)
* C-RP: c-reactive protein; MYO: myoglobine; MPO: myeloperoxidase; ** aa: aminoacids
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Discussion
The present systematic review has highlighted an in-
creased scientific interest toward the use of salivary 
biomarkers for diagnosis of systemic diseases and ma-
lignant tumors. Even limiting the field of interest only 
to diagnosis and applying strict inclusion and exclusion 
criteria, the number of papers appears considerable.
It is worthy to mention here that among the 79 papers 
included, only 12 studies were conducted before 2010, 
the rest being published after such year (12,23,25-34).
The most investigated salivary molecules are proteins 
(43 studies), followed by metabolites (15 studies) and 
RNA (12 studies). Surprisingly, the less studied sali-
vary biomarkers are those based on DNA (3 studies) 
and microbiota (2 studies) analysis, despite their popu-
larity for other aims (e.g ancestry investigations, bio-
compatibility for transplant, forensic analysis, dietary 
implications) (35,36).
In recent years, there has been a shifting of interest in 
the typology of molecules investigated. In fact, even 
if proteins remained predominant, there has been an 
increase of researches dealing with salivary metabo-
lites (16 papers in 2018 and 2 papers in the first half of 
2019) (37,38).
Most of the studies included in the present systematic 
review (69 out of 79 – 87%) showed statistically sig-
nificant correlations between one or more biomarkers 
and specific pathologies. Such results would, in general, 
indicate the possibility to use peculiar salivary mole-
cules for early diagnosis of diseases. However, critical 
appraisal and quality assessment highlighted that most 
of these studies did not satisfy a relevant percentage 
the items suggested by the NIH formats. As a matter of 
facts, only 19 studies received a score indicating “good” 
quality. Also, the level of evidence of all of the exam-
ined studies appears quite low.
One of the most frequently encountered ROBs was the 
lack of sample size justification. Calculation of a sample 
size is a fundamental step for creating reliable research-
es. Groups of patients too small have little chance of 
meeting the study objectives (39). Therefore, particu-
larly for studies on salivary biomarkers it seems very 
important to report the justification of the population 
size. On the other hand, it should be taken into account 
that several studies included in the present review were 
pilot studies (27,40). For such a typology of research, 
it is usually difficult to provide a statistical reliable 
sample size justification, on the basis of the absence of 
background data in the literature (41). It is opinion of the 
Authors of the present systematic review that, the de-
scribed ROB may largely depend on the fact that many 
of the studies took into consideration many variables at 
the same time (e.g. panel or combinations of very dif-
ferent biomolecules, biomarkers evaluated for the first 
time in saliva, patients with diseases at different stages), 
thus making more or less impossible to calculate a reli-
able sample size.
The second most frequently encountered ROBs involved 
the absence of blinding of exposure assessor. Blinding 
is important to remove bias that could influence the way 
the data is processed. The two major biases that can be 
controlled using blinding are the performance bias (dif-
ferences that occur due to knowledge of intervention al-
location, in either the researcher or the participant that 
cause differences in the care received) and the ascer-
tainment bias (when data for a study or analysis is col-
lected, surveyed, screened, or recorded, such that some 
members of the intended population are less likely to be 
included than others) (42). In the studies evaluated, the 
ROBs “absence of blindness” was induced by the fact 
that it was not specified if the biochemical analyst was 
or was not unaware of the provenance of the specimen 
(e.g. case or control group).
The most investigated disease in the present review was 
breast cancer (18 out of 79 studies), the most common 
malignant tumor among women (25% off all females 
tumors), with approximately 1.7 million new cases diag-
nosed every year (43). Fourteen studies (78%) reported 
statistically significant association between the pres-
ence of breast tumor and finding of one or more markers 
in patients saliva. Molecules such C-erbB2, CA 15-3, 
Cathepsin D, sialic acid and P53, EGF, VEGF and the 
CEA, seem to be promising salivary markers possibly 
very useful either for diagnosis of breast carcinoma and 
for follow-up of patients after treatment. According to 
the quality assessment tool adopted here, only one study 
dealing with breast cancer and salivary biomarkers ob-
tained a “good” quality score, its results being apparent-
ly very robust (6). However, such a study investigated a 
panel of proteins, detected trough the SERS technology, 
which are not yet completely characterized and identi-
fied (6). Therefore, the utility of these proteins is cur-
rently somewhat questionable and their role should be 
confirmed in further studies.
The second most studied malignant tumor, according 
to the present systematic review is lung carcinoma (10 
studies). Lung cancer is the most common cancer in 
humans (11.6% of all malignant tumours) and the lead-
ing cause of death for malignancy (18.4%) (44). All of 
the researches on patients with lung carcinomas pro-
vided statistically significant results to the association 
between salivary molecules and the pulmonary malig-
nancy. Specifically, molecules identified included a mu-
tation of the EGFR gene, 5 mRNA (CCNI, EGFR, FGF 
19, FRS 2, GREB1), several bacteria (e.g. Sphingomo-
nas, Blastomonas, Acinetobacter, Streptococcus) and 
proteins such as the calprotectin, alkaline phosphatase, 
cytokines, AZGP1 and haptoglobine (HP). All the re-
ported molecules showed a good statistical association 
with diagnosis of lung carcinomas at different stages of 
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developement. The “good” quality studies on salivary 
biomarkers and lung cancer are those demonstrating an 
association with EGFR, the 5 mRNA, microbiota and 
cytokines (8-11). According to the results of the present 
review they can be considered already reliable markers.
Data on association between salivary biomarkers 
and diagnosis of malignant tumors are available also 
for gastric and pancreatic cancer. Gastric cancer af-
fects approximately one million individuals per year 
worldwide, having a mortality rate of approximately 
(1.033.701 new cases in 2018 and 782.685 death in 
2018, in the world) (44). It is often detected late be-
cause up to 80 % of patients are asymptomatic during 
the early phases of disease (45). Similarly, pancreatic 
carcinoma is insidious, very aggressive and in most 
cases diagnosed at a very late stage, being associated 
to a very poor prognosis (46).
With regard to gastric cancer 7 studies were included 
in the present review (15-17,25,47-49). All of these re-
ported statistically significant results. The “good” qual-
ity studies were three and they were focused on salivary 
bacteria (Prevotella, Leptotrichia, Rothia, Aggregati-
bacter, Campylobacter, Megasphaera, Granulicatella), 
RNA (SPINK7, PPL, SEMA4B, miR140-5p, miR301a) 
and some lectins.
All of the studies on pancreatic cancer demonstrated 
a significant association between the salivary mol-
ecules and the disease. Two of these were also scored 
as “good” after quality assessment. Molecules reported 
in such analysis were derived from transcriptomics 
(4mRNA (KRAS, MBD3L2, ACRV1, DPM1), and 2 
miRNA (miR-3679-5p and miR-940)).
It is worthy to mention here that both for gastric and 
pancreatic cancer, the possibility of early diagnosis 
through salivary diagnostics, not based on the subjec-
tive radiographical images interpretation, could poten-
tially contribute to prevent most of the deaths related to 
such cancers (3).
Particularly in the field of oncology, an easy and non-
invasive method based on salivary biomarkers, may hy-
pothetically constantly monitor and screen saliva, thus 
detecting very recurrences very (50).
Studies on neurological disorders are focused on Par-
kinson’s and Alzheimer’s diseases. It is interesting to 
highlight that the use of salivary biomarkers in patients 
with neurological pathologies has gained a great inter-
est in the last couple of years (8 out 14 articles published 
in 2017-18). Such an increasing of interest might be ex-
plained taking into consideration that the diagnosis of 
these diseases are essentially clinical. The identification 
of objective features (including biomolecules within 
body fluid) seems therefore of paramount importance 
for diagnosis, monitoring of disease progression and 
management as well as the development of novel thera-
peutic interventions (51).
Among studies on inflammatory, cardiovascular and 
metabolic diseases those reporting significant results 
are focused on myocardial infarction and rheumatoid 
arthritis (20-24,26). 
Research on myocardial infarction searched C-reactive 
protein, myoglobin, myeloperoxidase, creatine phos-
phokinase, creatin kinase MB, cardiac troponin T and 
cathepsin-L, all reporting statistically significant result. 
In one of these studies the use a saliva-based nanochip 
was proposed (23). Such a new technology, based on 
nanotechnologies and innovative materials, is appar-
ently very promising, deserving further researches.
Rheumatoid arthritis is sometime difficult to diagnose, 
especially in early stages, because of the variability of 
the symptoms and the absence of specific markers (52). 
Early diagnosis of the disease usually improves the suc-
cess of treatment and could possibly reduce the quantity 
of drugs administered. In the study on included in the 
present review, Authors identified particularly one sali-
vary protein (GRP78/BiP) which was significantly as-
sociated to the disease (p<0.001, 83.3% sensitivity and 
95% specificity) (26).
A limit of the present systematic review is the lack of 
a quantitative analysis. The heterogeneity of diseases 
evaluated, their stage at diagnosis, the extremely wide 
range of molecules investigated as well as the differ-
ences in procedures for saliva collection, handling, stor-
ing and processing, makes it impossible to draw reliable 
pooled results or to perform a meta-analysis. On the 
other hand, the results of the present qualitative analysis 
can provide useful information in the field of salivary 
diagnostics. Particularly, the findings reported here can 
be the background for further studies which possibly 
might take into account the ROBs highlighted in the 
qualitative analysis of papers. Future studies might be 
useful to confirm and improve the potentiality of sali-
vary analysis techniques (in terms of sensitivity and 
specificity) as well as to develop new, smaller, patient-
friendly devices possibly with affordable costs.
Diffusion and ready availability of a panel of sensors 
for detecting salivary biomarkers associated to sys-
temic diseases could have a strong impact on public 
healthcare and economy. The use of saliva for analysis 
might replace the use of blood, with a possible eco-
nomic impact based on the easier and non-invasive 
method for collection (50). Such a perspective, may 
well lead to a higher commercial availability of screen-
ing assays (53) and possibly bring to the development 
of analytic tools directly administered in the dental or 
general physician office.
The use of salivary biomarkers for diagnosis of system-
ic diseases (“salivary diagnostics”) is gaining increas-
ing interest.
The present systematic review confirms the existence 
of some “good” quality evidence to support the role 
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of peculiar salivary biomarkers for diagnosis of sys-
temic diseases (e.g. lung cancer and EGFR). However, 
it seems necessary to encourage further researches for 
improving the sensitivity and specificity of salivary 
diagnostics analysis.
The perspective of realizing a reliable “lab-on-a-chip” 
for diagnosis and follow-up of systemic diseases and/or 
malignant tumors through saliva evaluation seems an 
attainable target of modern medicine.
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